20/20 Biolabs (NASDAQ:AIDX) Announces Earnings Results

20/20 Biolabs (NASDAQ:AIDX – Get Free Report) announced its quarterly earnings data on Monday. The company reported ($0.12) EPS for the quarter, Zacks reports.

20/20 Biolabs Trading Down 9.4%

20/20 Biolabs stock traded down $0.02 during mid-day trading on Monday, hitting $0.18. The company’s stock had a trading volume of 138,569 shares, compared to its average volume of 395,094. The stock’s fifty day moving average is $0.35 and its two-hundred day moving average is $0.95. The firm has a market capitalization of $2.47 million and a PE ratio of -0.34. 20/20 Biolabs has a 1 year low of $0.18 and a 1 year high of $50.00.

Analysts Set New Price Targets

Separately, Weiss Ratings raised shares of 20/20 Biolabs from a “sell (e)” rating to a “sell (e+)” rating in a report on Friday. One research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, 20/20 Biolabs currently has a consensus rating of “Hold” and a consensus target price of $5.00.

Read Our Latest Research Report on AIDX

About 20/20 Biolabs

(Get Free Report)

20/20 BioLabs is a clinical laboratory company that has provided diagnostic testing services, with a focus on infectious diseases. Its offerings have included COVID-19 testing, such as molecular and antibody-based tests, along with related laboratory services. The company became known during the COVID-19 pandemic, when it supported demand for testing in the United States. Publicly available information about its broader operations and leadership is limited.

Featured Articles

Receive News & Ratings for 20/20 Biolabs Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for 20/20 Biolabs and related companies with MarketBeat.com's FREE daily email newsletter.